RLYB PE Ratio & Valuation,Is RLYB Overvalued

RLYB Relative Valuation

RLYB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, RLYB is overvalued; if below, it's undervalued.

Historical Valuation

Rallybio Corp (RLYB) is now in the Fair zone, suggesting that its current forward PS ratio of 231.98 is considered Fairly compared with the five-year average of -2.36. The fair price of Rallybio Corp (RLYB) is between 0.06 to 0.95 according to relative valuation methord.

Relative Value

Fair Zone

0.06-0.95

Current Price：0.73

Fair

-1.15

0.00

EV/EBITDA

Rallybio Corp. (RLYB) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -0.18. The thresholds are as follows: Strongly Undervalued below -1.98, Undervalued between -1.98 and -1.08, Fairly Valued between 0.72 and -1.08, Overvalued between 0.72 and 1.62, and Strongly Overvalued above 1.62. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.93

EV/EBIT

Rallybio Corp. (RLYB) has a current EV/EBIT of 0.93. The 5-year average EV/EBIT is -1.08. The thresholds are as follows: Strongly Undervalued below -6.72, Undervalued between -6.72 and -3.90, Fairly Valued between 1.74 and -3.90, Overvalued between 1.74 and 4.56, and Strongly Overvalued above 4.56. The current Forward EV/EBIT of 0.93 falls within the Historic Trend Line -Fairly Valued range.

231.98

Rallybio Corp. (RLYB) has a current PS of 231.98. The 5-year average PS is 71.03. The thresholds are as follows: Strongly Undervalued below -235.05, Undervalued between -235.05 and -82.01, Fairly Valued between 224.07 and -82.01, Overvalued between 224.07 and 377.12, and Strongly Overvalued above 377.12. The current Forward PS of 231.98 falls within the Overvalued range.

0.00

P/OCF

Rallybio Corp. (RLYB) has a current P/OCF of 0.00. The 5-year average P/OCF is -2.46. The thresholds are as follows: Strongly Undervalued below -7.33, Undervalued between -7.33 and -4.90, Fairly Valued between -0.02 and -4.90, Overvalued between -0.02 and 2.42, and Strongly Overvalued above 2.42. The current Forward P/OCF of 0.00 falls within the Overvalued range.

0.00

P/FCF

Rallybio Corp. (RLYB) has a current P/FCF of 0.00. The 5-year average P/FCF is -5.80. The thresholds are as follows: Strongly Undervalued below -20.51, Undervalued between -20.51 and -13.16, Fairly Valued between 1.55 and -13.16, Overvalued between 1.55 and 8.90, and Strongly Overvalued above 8.90. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Rallybio Corp (RLYB) has a current Price-to-Book (P/B) ratio of 0.49. Compared to its 3-year average P/B ratio of 0.81 , the current P/B ratio is approximately -39.28% higher. Relative to its 5-year average P/B ratio of 1.09, the current P/B ratio is about -55.30% higher. Rallybio Corp (RLYB) has a Forward Free Cash Flow (FCF) yield of approximately -113.17%. Compared to its 3-year average FCF yield of -110.01%, the current FCF yield is approximately 2.88% lower. Relative to its 5-year average FCF yield of -79.30% , the current FCF yield is about 42.72% lower.

0.49

P/B

Median3y

0.81

Median5y

1.09

-113.17

FCF Yield

Median3y

-110.01

Median5y

-79.30

Competitors Valuation Multiple

The average P/S ratio for RLYB's competitors is 46.16, providing a benchmark for relative valuation. Rallybio Corp Corp (RLYB) exhibits a P/S ratio of 231.98, which is 402.59% above the industry average. Given its robust revenue growth of -29.10%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of RLYB decreased by 23.75% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -0.58 to -2.33.

The secondary factor is the Revenue Growth, contributed -29.10%to the performance.

Overall, the performance of RLYB in the past 1 year is driven by P/E Change. Which is more unsustainable.

-29.10%

299.00K → 212.00K

Revenue Growth

-297.01%

-3.83K → 7.55K

Margin Expansion

302.36%

-0.58 → -2.33

P/E Change

-23.75%

0.96 → 0.73

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Rallybio Corp (RLYB) currently overvalued or undervalued?

What is Rallybio Corp (RLYB) fair value?

RLYB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Rallybio Corp (RLYB) is between 0.06 to 0.95 according to relative valuation methord.

How does RLYB's valuation metrics compare to the industry average?

What is the current P/B ratio for Rallybio Corp (RLYB) as of Dec 15 2025?

As of Dec 15 2025, Rallybio Corp (RLYB) has a P/B ratio of 0.49. This indicates that the market values RLYB at 0.49 times its book value.

What is the current FCF Yield for Rallybio Corp (RLYB) as of Dec 15 2025?

As of Dec 15 2025, Rallybio Corp (RLYB) has a FCF Yield of -113.17%. This means that for every dollar of Rallybio Corp’s market capitalization, the company generates -113.17 cents in free cash flow.

What is the current Forward P/E ratio for Rallybio Corp (RLYB) as of Dec 15 2025?

As of Dec 15 2025, Rallybio Corp (RLYB) has a Forward P/E ratio of -1.15. This means the market is willing to pay $-1.15 for every dollar of Rallybio Corp’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Rallybio Corp (RLYB) as of Dec 15 2025?

As of Dec 15 2025, Rallybio Corp (RLYB) has a Forward P/S ratio of 231.98. This means the market is valuing RLYB at $231.98 for every dollar of expected revenue over the next 12 months.

RLYB Valuation

RLYB Valuation

RLYB Relative Valuation

Historical Valuation

Competitors Valuation Multiple

Performance Decomposition

People Also Watch

Frequently Asked Questions

Is Rallybio Corp (RLYB) currently overvalued or undervalued?

What is Rallybio Corp (RLYB) fair value?

How does RLYB's valuation metrics compare to the industry average?

What is the current P/B ratio for Rallybio Corp (RLYB) as of Dec 15 2025?

What is the current FCF Yield for Rallybio Corp (RLYB) as of Dec 15 2025?

What is the current Forward P/E ratio for Rallybio Corp (RLYB) as of Dec 15 2025?

What is the current Forward P/S ratio for Rallybio Corp (RLYB) as of Dec 15 2025?